Inpharma

Calls to axe pharmaceutical tariffs in WTO talks
pp. 2-2(1)

Stop TB Strategy launched by WHO
pp. 2-2(1)

TGN 1412: learning from adversity
pp. 3-3(1)

α-Blockers and TURP cost effective long-term for BPH
pp. 3-3(1)

New tuberculosis treatments on the horizon
pp. 3-3(1)

Losartan beats atenolol in hypertension with LVH
pp. 4-4(1)

Long-term goserelin does not deprive prostate cancer patients
pp. 4-4(1)

Long-term adefovir dipivoxil cost effective in chronic hep B
pp. 4-4(1)

ISA 247: potential in the psoriasis pipeline
pp. 5-6(2)

Immunisation facilitates HAART interruption
pp. 7-7(1)

Viramidine looks hopeful in hepatitis C
pp. 7-7(1)

A new chemotherapy regimen in which pixantrone replaces doxorubicin in CHOP is beneficial in relapsed non-Hodgkin's lymphoma
pp. 7-7(1)

The selective 5-HT2A receptor inverse agonist ACP 103 may be beneficial for Parkinson's disease patients with treatment-induced psychosis
pp. 7-7(1)

If at first you don't succeed with an SSRI . . .
pp. 8-8(1)

E. coli vaccine: a little goes a long way in Bangladeshi infants
pp. 8-8(1)

The addition of intrauterine lidocaine (4%) to a lidocaine paracervical block eases pain during first-trimester abortions
pp. 8-8(1)

Candesartan a TROPHY winner in preventing hypertension
pp. 9-10(2)

The angiotensin receptor blocker valsartan is as effective in reducing the risk of atherosclerotic events as captopril
pp. 11-11(1)

The benefits of omega-3 fatty acids may be a bit fishy
pp. 11-11(1)

Low-dose bendroflumethiazide is efficacious in the treatment of mild-to-moderate hypertension
pp. 11-11(1)

Fludarabine + cyclophosphamide effective in CLL
pp. 11-11(1)

Children with suspected meningococcal disease who receive parenteral penicillin from a general practitioner have poorer outcomes
pp. 12-12(1)

Donepezil an advantage in severe Alzheimer's disease
pp. 12-12(1)

Ropivacaine adds satisfaction and spares opioids after TKA
pp. 12-12(1)

Single-dose famciclovir effective in herpes labialis
pp. 12-12(1)

Low-dose acitretin provides considerable benefit for patients with moderate-to-severe plaque psoriasis
pp. 12-12(1)

Controlled-release doxycycline changing the face of rosacea
pp. 13-14(2)

Statins reduce VT/VF risk in ICD patients
pp. 14-14(1)

Hypericum plus cimicifuga effective in menopausal syndrome
pp. 14-14(1)

Aspirin suppresses platelet reactivity in both sexes
pp. 15-15(1)

Liposomal amphotericin B colloidal dispersion is an effective treatment for visceral leishmaniasis
pp. 15-15(1)

Immunisation with pneumococcal 7-valent CRM197 conjugate vaccine (PC-7) leads to an immune response in HIV-infected adults
pp. 15-15(1)

Fetal metformin exposure approaches metformin concentrations in the maternal circulation
pp. 15-15(1)

Calcium dobesilate reduces myocardial injury biomarkers and protects the myocardium during open-heart surgery
pp. 15-15(1)

Increased bleeding with GP IIb-IIIa antagonist use
pp. 16-16(1)

Pactimibe not effective in atherosclerosis
pp. 16-16(1)

Bupropion appears to be associated with higher adverse event (AE) rates
pp. 16-16(1)

The addition of amisulpride to clozapine appears to reduce clozapine-induced sialorrhoea
pp. 16-16(1)

Statin use linked with impotence
pp. 17-17(1)

Product launches in India
pp. 17-17(1)

US product approvals
pp. 17-17(1)

Antidepressant use may increase risk of death in CAD
pp. 17-17(1)

EU product approvals
pp. 18-18(1)

Other EU regulatory news
pp. 18-18(1)

Other US regulatory news
pp. 18-18(1)

Chiron Corporation has launched daptomycin [Cubicin] in the UK and The Netherlands for the treatment of complicated skin and soft-tissue infections
pp. 18-18(1)

Infliximab [Remicade; Schering-Plough] has received expanded approval for early rheumatoid arthritis (RA) and psoriatic arthritis in Australia
pp. 18-18(1)

Trastuzumab [Herceptin; Genentech, Roche] has been provisionally approved in New Zealand
pp. 18-18(1)

A Hib-DTP-hepatitis B vaccine [Quinvaxem; Berna Biotech, Chiron Corporation] has been awarded licensure by the Korea Food and Drug Administration
pp. 18-18(1)